statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024...

Ligand to Acquire APEIRON Biologics AG for $100 Million

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA (dinutuximab...

What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals

Latest Ratings for LGND
 DateFirmActionFromTo Feb 2022BenchmarkMaintainsBuy Feb 2022BarclaysMaintainsOverweight Sep 2021BarclaysMaintainsOverweight
 View More Analyst Ratings for LGND...

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration (FDA) for Ohtuvayre...

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval from the U.S. Food and Drug...

Ligand to Participate in Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participate in the following upcoming...

Ligand Reports First Quarter 2024 Financial Results

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand...

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the...

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and...

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Volume	88,710.00
52-Wk High	$108.91
52-Wk Low	$49.24

LGND Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

About

Feed

News

Sentiment

Earnings

Fundamentals